Background: The purpose of this retrospective study was to investigate the predictive ability of the Ki67 labeling index (LI) for relapse-free survival (RFS) of patients with stage I-II invasive breast cancer after breast-conserving therapy. Materials and methods: Between 2012 and 2016, 240 patients with stage I-II invasive breast cancer were treated at our hospital with breast-conserving therapy. Survival outcomes were analyzed using the Kaplan-Meier and cumulative incidence methods. Factors including T stage, N stage, estrogen receptor, HER2, and Ki67 LI were evaluated with regard to RFS using Cox proportional hazard regression. Results: The median duration of follow-up in the surviving patients was 36 months (range, 14-62 months). Rates of 3-year overall survival and RFS were 98.1% and 96.4%, respectively. Three-year cumulative rates of local recurrence, regional recurrence, and distant metastasis were 1.3%, 1.2%, and 2.1%, respectively. Multivariate analysis revealed that a Ki67 LI ≥33.3% was the only prognostic factor for RFS. Conclusion: A Ki67 LI ≥33.3% was a predictor of significantly worse RFS.
Introduction
The survival rates after mastectomy or breastconserving therapy (BCT) to treat invasive stage I-II breast cancer are equivalent, 1)2) and BCT is recommended as a first-line treatment. 3) Since 2003, BCT has been performed more often than mastectomy to treat invasive stage I-II breast cancer in Japan. 4) Local treatment during BCT includes BCT itself and the administration of postoperative radiotherapy to the entire breast on the affected side. Postoperative radiotherapy decreases postoperative recurrence by one third and improves the survival rate. 5)6) Meanwhile, information on the T and N stage and immunohistochemistry including information on estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki67 labeling index (LI) status are used to select concomitant systemic treatment. 7)8) Ki67, a protein marker of cell proliferation, has been considered a prognostic factor for breast cancer in research to date, 9) 10) although its method of evaluation has not been standardized yet. Although the consensus is that Ki67 LI can be used as an index for separating breast cancer into luminal A and luminal B subtypes, quantitativeness has been inconsistent and the cut-off value has not been clari-fied, both of which are considered problematic. At the St. Gallen International Expert Consensus Conference, at which treatment guidelines for breast cancer are decided, the cut-off value was changed from 14% to 30%, but this value has not been unanimously agreed upon yet. At the 2017 conference, it was recommended that the cut-off value should be decided at each facility, and therefore, it is necessary to determine the cut-off value at our hospital. In this paper, we investigated the predictive ability of the Ki67 LI for relapse-free survival (RFS) in patients with stage I-II invasive breast cancer after BCT and determined a cut-off value for the Ki67 LI at our hospital.
Patients and Methods

Patients
We conducted our retrospective study in 240 patients with positive infiltration of the resection margin selected from the patients who underwent BCT to treat invasive stage I-II breast cancer at St. Marianna University Hospital from July 2012 to January 2016. Positive infiltration of the resection margin was defined as cancer present either within the resection margin itself or ≤5 mm from the margin.
Immunohistochemical (IHC) evaluation
Samples were fixed in 15% formalin, embedded in paraffin, and subjected to IHC analysis for ER, HER2, and Ki67. ER expression was considered positive when >1% positive cells were present in an evaluated area. HER2 expression was detected using the DAKO HercepTest (DakoCytomation, Carpinteria, CA) or amplification of the HER2 gene that was present using the fluorescence in situ hybridization (FISH) method. The Ki67 antibody as the primary antibody (Clone MIB1; DAKO, Glostrup, Denmark) was used to detect Ki67 expression. Briefly, the stained slides were first observed by pathologists using low-power magnification, and after 3-5 areas were selected for estimation under high-power magnification, one or two pathologists estimated the ratio of positive/negative cells in each area, and the average ratio of positive cells in all evaluated areas was reported as the Ki67 LI. The Ki67 LI was classified as 1, 2, 3, 4, or 5 using a simple 5-grade scale called the Eye-5 11) . Cut-off points were set at ratios of 1/9 (10%), 1/6 (14.3%), 1/2 (33.3%), and 1/1 (50%). Eye-5 grades were as follows: 1 = Ki67 LI 0-9%, 2 = 10-14.2%, 3 = 14.3-33.2%, 4 = 33.3-49.9%, and 5 = ≥50%.
Treatment methods Surgery
Partial breast resection (Bp) was performed to treat the primary tumor. We performed a sentinel lymph node (SLN) biopsy if the axillary lymph nodes (ALN) were clinically negative. If the SLN was positive, then we performed an ALN dissection or administered radiotherapy to the axillary, infraclavicular, and supraclavicular lymph nodes. ALN dissection was performed if the nodes were clinically positive.
Radiotherapy
Computed tomography (CT) was used to plan radiotherapy using a slice thickness of 5 mm. We used the XiO version 5.10 (Elekta, Stockholm, Sweden) or Pinnacle 3 version 9.10 (Philips Healthcare, Amsterdam, Netherlands) application to perform three-dimensional radiotherapy planning. The clinical treatment volume (CTV) for whole-breast irradiation was the entire breast on the affected side. Tangential field irradiation was performed, and the radiotherapy dose distribution was equalized using the field-infield technique. After whole-breast radiation, boost irradiation was administered to the tumor bed. A surgical clip was placed on the tumor bed margin intraoperatively, and postoperative seroma on the treatment planning CT images was used to boost the CTV. A 5mm margin was added to the CTV boost to create a planning treatment volume (PTV) boost. If the PTV boost depth was shallow (<2 cm between the skin and the radiation dose evaluation point), electron beams were used. And if the PTV boost depth was comparatively deep (≥2 cm between the skin and the radiation dose evaluation point), then X-rays were used. An electron beam energy of 6-12 MeV was selected based on the PTV boost depth (electron boost). If Xrays were used, then we performed three-dimensional conformal irradiation (photon boost) using a coplanar beam with 4 or 5 portals for the PTV boost. There were 173 patients treated using an electron boost and 67 treated using a photon boost. ALN dissection was omitted in five patients, despite the presence of ≥4 ALN metastases or positive SLN metastases, and these five patients received axillary, infraclavicular, and supraclavicular radiation therapy. The X-rays were delivered at 4 or 6 MV, and we used a PRIMUS High-Energy KD2-7467 (Toshiba Medical Systems, Tochigi, Japan) or Synergy (Elekta) linear accelerator. The fractionation schedules for radiotherapy were hypo-fractionation and standard fractionation. Standard fractionation was selected for N1 patients, pa-tients receiving chemotherapy, and patients who received infraclavicular and supraclavicular radiotherapy.
Other patients were provided with an explanation that the outcomes of patients treated in clinical trials 12) with both methods were equivalent, and the patients chose the method themselves. During standard fractionation, a dose of 50 Gy/25 fr was administered to the whole breast, followed by a PTV boost of 10 Gy/5 fr, giving a total dose of 60 Gy/30 fr. During hypo-fractionation, a dose of 42.56 Gy/16 fr was administered to the whole breast, followed by a PTV boost of 10.64 Gy/4 fr, giving a total dose of 53.2 Gy/20 fr.
Endocrine therapy, anti-HER2 therapy, and chemotherapy
The attending physician determined the indications for endocrine therapy, anti-HER2 therapy, and chemotherapy based on T stage, N stage, ER, HER2, Ki67 LI, and age. Chemotherapy was administered to all HER2-positive and to all ER-negative + HER2negative patients as a rule.
Follow-up
Patients were followed up at 3-to 6-month intervals after treatment ended. Plain X-ray images, mammography, and ultrasound examination of the breast were performed at 6-month intervals. CT, magnetic resonance imaging, bone scan, and 18-fluorodeoxyglucosepositron emission tomography were performed as required.
Statistical analysis
The survival rate was determined with the Kaplan-Meier method using the date of resection as the origin, which was then used to calculate overall survival (OS) and RFS. Local recurrence in the affected breast was confirmed histopathologically. The imaging diagnosis was used to detect regional and distant metastases. The earliest date on which local, regional, or distant recurrence was confirmed was considered to be an event and was used to calculate the RFS.
Factors influencing the RFS were analyzed using the Cox proportional hazard regression. The following factors were investigated: T stage (T1 vs. T2), N stage (N0 vs. N1), ER (negative vs. positive), HER2 (negative vs. positive), Ki67 LI (Eye-5 grade 1-3 vs. 4-5). Univariate analysis was performed and factors with p<0.5 were used to perform multivariate analysis. Ultimately, factors with p<0.05 were considered statistically significant. The cumulative recur-rence rate was calculated using the cumulative incidence method, and we also calculated the rates of local recurrence (LR), regional recurrence (RR), and distant metastasis (DM). Fine and Gray's method was used to compare recurrence rates. R ver. 3.4.1 software was used to perform statistical analysis. This retrospective study was performed after approval from the institutional review board of St. Marianna University (approval no. 2997), and written consent was obtained from all patients.
Results
Patient, tumor, and treatment characteristics ( Table 1) Adenocarcinoma was confirmed in all patients. The median patient age was 50 years (28-83 years). The affected site was on the left breast in 118 patients and the right breast in 122 patients. The TNM Classification of Malignant Tumors (Union for International Cancer Control, 8th edition) was T1N0M0 in 134, T1N1M0 in 35, T2N0M0 in 40, and T2N1M0 in 31 patients.
The Eye-5 classifications were 1, 2, 3, 4, and 5 in 46, 77, 82, 22, and 13 patients, respectively. Among the patients, 223 tested ER positive and 17 tested ER negative. The rates of ER-positive patients with Eye-5 classifications 1, 2, 3, 4, and 5 were 100%, 97.4%, 98.7%, 77.2%, and 30.7%, respectively ( Fig. 1) . Forty-four patients tested HER2 positive, and 196 patients tested HER2 negative. By subtype, 189 patients tested ER positive and HER2 negative, 34 tested ER positive and HER2 positive, 10 tested ER negative and HER2 positive, and 7 tested ER negative and HER2 negative.
A flow chart of the treatment is shown in Fig. 2 anthracycline-based regimen alone, and 30 patients received taxane alone or a taxane-based regimen.
Determination of an optimal Ki67 LI cut-off value
RFS decreased as the Eye-5 value increased, and the difference in RFS widened significantly as the cut-off value increased. For Eye-5 grade 1 vs. 2-5, there was no significant difference in RFS (by logrank test, p=0.16), whereas for Eye-5 grade 1-2 vs. 3-5, there was a significant difference in RFS (p=0.02). However, univariate analysis using Cox proportional hazard regression showed no significant difference (p=0.058) in the Eye-5 grade 1-2 vs. 3-5 hazard ratio, whereas the Eye-5 grade 1-3 vs. 4-5 hazard ratio was significantly different (p<0.01). Similarly, in the multivariate analysis, the Eye-5 grade 1-2 vs. 3-5 hazard ratio showed no significant difference (p=0.3), but the Eye-5 grade 1-3 vs. 4-5 hazard ratio was significantly different (p=0.03). Therefore, the cut-off value of Eye-5 grade in this study was set at 1-3 vs. 4-5.
Outcomes
The median period of follow-up observation for the surviving patients was 36 months (range: 14-62 months). Three patients died; two from the primary disease and one from gastric cancer. Eight patients experienced recurrence: as LR in 3 patients, RR in 1, DM in 3, and DM and RR simultaneously in 1 patient. LR only occurred in 2 patients, LR and DM in 1 patient, RR and DM in 2 patients, and DM only in 3 patients.
Survival rates
The three-year OS was 98.1% (95% CI: 95.9-100%), and the three-year RFS was 96.4% (95% CI: 94-98.9%). Fig. 3 shows the RFS by T stage (T1 vs. T2), N stage (N0 vs. N1), ER (negative vs. positive), HER2 (negative vs. positive), and Ki67 LI (Eye-5 grade 1-3 vs. 4-5). The 3-year RFS by T stage was 97.9% in T1 patients and 92.9% in T2 patients (p=0.03). The 3-year RFS by N stage was 98.1% in N0 patients and 92.4% in N1 patients (p=0.02). The 3-year RFS by ER status was 76.5% in ER-negative patients and 98.0% in ER-positive patients (p<0.01). The 3-year RFS by HER2 status was 97.1% in HER2-negative patients and 93.2% in HER2-positive patients (p=0.16). The 3-year RFS by Ki67 LI stage was 98.8% in Eye-5 grade 1-3 patients and 82.9% in Eye-5 grade 4-5 patients (p<0.01).
Cumulative recurrence rates
The three-year rate of LR was 1.3%, that of RR was 1.2%, and that of DM was 2.1%. Fig. 4 shows the LR, RR, and DM rates by Eye-5 classification. In the Eye-5 grade 1-3 patients and grade 4-5 patients, the respective three-year rates of LR were 0.6% and 5.7% (p=0.04), those of RR were 0.0% and 8.5% (p<0.01), and those of DM were 0.5% and 11.4% (p<0.01).
Univariate and multivariate analysis ( Table 2) The factors T stage, N stage, ER, HER2, and Ki67 LI had a p value <0.05 during univariate analysis. The only factor with a p value <0.05 during mul- tivariate analysis was Ki67 LI. The hazard ratio for recurrence when the Ki67 LI was ≥33.3% compared with that when the Ki67 LI was <33.3% was 8.37 (95% CI 1.15-60.67), p=0.03.
Discussion
Ki67 is a protein expressed by the nucleus during stages of the cell cycle other than G0 and causes cell proliferation. If a high rate of Ki67 is observed in cancer tissues, then the cells are considered to possess proliferative ability and a high degree of malignancy. Studies to date have confirmed that high Ki67 LI values are a prognostic factor for breast cancer. 9)10) The St. Gallen International Expert Consensus Conference on the treatment of patients with primary breast cancer (St. Gallen International Expert Consensus Conference) 2011 13) used Ki67 LI as an indicator for the risk of recurrence in hormone receptorpositive and HER2-negative patients and divided the patients into a low-risk group, luminal A, and a highrisk group, luminal B. The consensus conference sub- 15) , 20% in 2013 15) , and <10% as the low and >30% as the high value in 2015 16) . Intermediate patients were defined as those with Ki67 LI values of 10-30%, and if we were not sure whether these patients were eligible for chemotherapy, a multigene expression test was effective in helping to better determine treatment decisions. During this study, we found that Ki67 LI values ≥33.3% in patients from our hospital with invasive stage I-II breast cancer treated with BCT were associated with poorer RFS. These results are consistent with those from the 2015 St. Gallen International Expert Consensus Conference. When we investigated the site of recurrence in patients with Ki67 LI ≥33.3%, we found significant increases in LR, RR, and DM in them. The reasons for a Ki67 LI ≥33.3% being associated with poorer RFS may be that LR increases when the degree of malignancy and resistance to radiotherapy increase, and the rate of indication for endocrine therapy decreases as the ER-positive rate decreases, which increases LR, RR, and DM. Improvement is needed in the future to reduce the inter-facility and pathologist variability of the Ki67 LI. In this study, we used the Eye-5 grading scale to evaluate the Ki67 LI. The Eye-5 grading scale based on visual measurement has been reported to be a system that can grade Ki67 LI values calculated by multiple pathologists with high reproducibility 11) . In the future, however, Ki67 LI measurement might be fundamentally improved by the use of computerized digital analysis 17) .
During the 2015 and 2017 St. Gallen International Expert Consensus Conferences, the multigene expression test was recommended more than the Ki67 LI values for ER-positive and HER2-negative patients if it is unclear whether these patients meet the indications for chemotherapy 14)15) . The multigene expression test has superior reproducibility but is more expensive, and about four weeks are required before results can be obtained. As mentioned above, although the test can be used by anyone, the differences in reproducibility between hospitals and pathologists is a challenge, so we thought that it would be meaningful to investigate cut-off values at our hospital.
There were some limitations during this study. This was a retrospective study design, the period of follow-up observation was too short to evaluate breast cancer treatment outcomes, and only one pathologist determined the Ki67 LI for some of the specimens in this study. In the future, Ki67 LI measurement might be fundamentally improved by the use of computerized digital analysis. Going forward, we will need to perform studies with longer periods of follow-up observation. In conclusion, a Ki67 LI value ≥33.3% in patients with invasive stage I-II breast cancer treated with BCT was associated with increased LR, RR, and DM and poorer RFS.
